🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being hailed as a "significant breakthrough" in the effort against increasingly resistant strains of the pathogen, according to researchers.

An International Public Health Issue

The sexually transmitted infection are on the rise globally, with data suggesting over 82 million infections each year. Especially elevated rates are seen in the African continent and nations within the World Health Organization's designated area, which includes China and Mongolia to New Zealand. In England, cases have hit a all-time high, while infection numbers across Europe in 2023 were triple the level compared to the rates from 2014.

“The approval of new treatments for gonorrhoea is an critical and opportune development in the reality of growing infection rates, increasing antimicrobial resistance and the highly restricted treatment choices at this time.”

Medical experts are deeply concerned about the increase in treatment-resistant strains. The World Health Organization has designated it as a "critical concern". Recent surveillance showed that the effectiveness of standard treatments like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Two New Drugs Receive Approval

Zoliflodacin, alternatively called Nuzolvence, was authorized by the US Food and Drug Administration in December for use against gonorrhoea. This infection can lead to serious health problems, including the inability to conceive. Scientists hope that specific application of this new drug will help slow the development of resistance.

Gepotidacin, originating from the drugmaker GSK, was also approved in close succession. This medication, which is additionally indicated for UTIs, was shown in trials to be effective against superbug versions of the gonorrhoea bacteria.

An Innovative Partnership

This new treatment stemmed from a innovative non-profit model for antibiotic development. The non-profit organisation GARDP worked alongside the pharmaceutical company Innoviva to bring it to fruition.

“This authorization marks a major breakthrough in the treatment of highly resistant gonorrhoea, which previously has been staying ahead of our drug pipeline.”

Testing Outcomes and Worldwide Availability

According to findings released by a prominent scientific publication, the new drug eradicated the vast majority of genital gonorrhoea infections. This establishes an similar efficacy with the current standard treatment, which combines a dual-drug approach. The study involved hundreds of patients from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its collaboration, GARDP has the authority to make available and distribute the drug in numerous low-income and middle-income countries.

Clinicians directly involved have shared hope. Access to a single-dose, oral treatment like this is hailed as a "revolutionary step" for public health efforts. This is considered essential to lessen the impact of the illness for individuals and to halt the transmission of highly drug-resistant gonorrhoea worldwide.